Eledon Pharmaceuticals (ELDN) Stock Price, Quote, News & History | Benzinga

Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote, News & History

ELDNNASDAQ

Trade with Public

Trade with Public

$3.77

0.020.53%

Last update: Aug 12, 7:59 PM

$3.75

N/A

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.75

Close

$3.77

Volume / Avg.

796.31K / 1.30M

Day Range

$3.69 - $3.81

52 Wk Range

1.35 - 4.60

Market Cap

$289.45M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

54

Short Interest

8.05%

Days to Cover

6.49

Recent Eledon Pharmaceuticals Inc News

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.

Avi Kapoor

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.

Avi Kapoor

EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission

NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into human trials.

Akanksha Bakshi

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.

Vandana Singh

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study

Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney function data remain encouraging.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-68.89M

Investing Cash Flow (TTM)

12.86M

Financing Cash Flow (TTM)

53.69M

Free Cash Flow (TTM)

-68.89M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-2.34M

Analyst Trends and Forecast

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$178.53M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

6.46

Earnings Yield % (TTM)

-20.56%

Earnings Yield % (FWD)

-24.30%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.58

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$6.15M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.75

Close

$3.77

Volume / Avg.

796.31K / 1.30M

Day Range

$3.69 - $3.81

52 Wk Range

1.35 - 4.60

Market Cap

$289.45M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

54

Short Interest

8.05%

Days to Cover

6.49

About

Sector

Health Care

Industry

Biotechnology

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Eledon Pharmaceuticals (ELDN) stock?

A

You can purchase shares of Eledon Pharmaceuticals (NASDAQ:ELDN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Eledon Pharmaceuticals (ELDN) competitors?

A

Other companies in Eledon Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Eledon Pharmaceuticals (ELDN) stock?

A

Eledon Pharmaceuticals has a consensus price target of $10.86.

Q

What is the current price for Eledon Pharmaceuticals (ELDN)?

A

The stock price for Eledon Pharmaceuticals (NASDAQ: ELDN) is $3.75 last updated August 12, 2026 at 7:59 PM EDT.

Q

Does Eledon Pharmaceuticals (ELDN) pay a dividend?

A

There are no upcoming dividends for Eledon Pharmaceuticals.

Q

When is Eledon Pharmaceuticals (NASDAQ:ELDN) reporting earnings?

A

Eledon Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Eledon Pharmaceuticals (ELDN) going to split?

A

There is no upcoming split for Eledon Pharmaceuticals.

Q

What sector and industry does Eledon Pharmaceuticals (ELDN) operate in?

A

Eledon Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.